Recent research suggests that exercise can be effective in reducing pain in animals and humans with neuropathic pain. To investigate mechanisms in which exercise may improve hyperalgesia associated with prediabetes, C57Bl/6 mice were fed either standard chow or a high-fat diet for 12 weeks and were provided access to running wheels (exercised) or without access (sedentary). The high-fat diet induced a number of prediabetic symptoms, including increased weight, blood glucose, and insulin levels. Exercise reduced but did not restore these metabolic abnormalities to normal levels. In addition, mice fed a highfat diet developed significant cutaneous and visceral hyperalgesia, similar to mice that develop neuropathy associated with diabetes. Finally, a high-fat diet significantly modulated neurotrophin protein expression in peripheral tissues and altered the composition of epidermal innervation. Over time, mice that exercised normalized with regards to their behavioral hypersensitivity, neurotrophin levels, and epidermal innervation. These results confirm that elevated hypersensitivity and associated neuropathic changes can be induced by a high-fat diet and exercise may alleviate these neuropathic symptoms. These findings suggest that exercise intervention could significantly improve aspects of neuropathy and pain associated with obesity and diabetes. Additionally, this work could potentially help clinicians determine those patients who will develop painful versus insensate neuropathy using intraepidermal nerve fiber quantification.
Introduction
Diabetic neuropathy (DN) occurs in up to 60-70% of diabetes patients. Distal symmetric DN is the most common neuropathy associated with diabetes and may present with either positive (pain, burning, or tingling) or negative symptoms (numbness or altered proprioception) [45] . Neuropathy symptoms can precede diagnosis of diabetes and may develop in the initial stages of glucose dysregulation, or prediabetes [14, 40] , with prediabetes being defined as impaired fasting glucose and/or impaired glucose tolerance [3] . Although neuropathy associated with prediabetes is usually less severe than neuropathy in overt diabetic patients [51] , it is still a devastating complication of the disease. Unfortunately, painful symptoms are the predominant feature in prediabetes patients. Current treatment options for patients with painful diabetic neuropathy (PDN) are rarely effective and less than 30% of patients achieve satisfactory pain relief [4] .
Recent studies have demonstrated that cutaneous nerve growth factor (NGF) is increased in hind paw skin of rodent models of type 1 and type 2 diabetes [9,15]. It has been suggested that increased NGF may play a significant role in the development of PDN. Additionally, NGF is known to be critical in the development and maintenance of chronic pain, especially inflammatory pain [30, 43] . In fact, cutaneous injections of NGF result in thermal and mechanical hyperalgesia in both animals and humans [33] . Besides NGF, additional neurotrophins that play a role in pain sensation include brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF). Like NGF, BDNF is believed to play a role in the development and maintenance of pain states, as BDNF is upregulated in the dorsal root ganglion (DRG) in inflammatory conditions and in models of neuropathic pain [32] . Furthermore, delivery of antibodies against BDNF reduced pain related behaviors in rat [60] and mouse [59] . Although NGF and BDNF are important for the development and maintenance of pain, GDNF is believed to play an antinociceptive role. Previous studies have shown that administration of exogenous GDNF results in analgesia in various models of neuropathic pain [1, 6] .
